Clinical Trials Browser

Phase 1 × Interventional × regorafenib × Clear all

NCT07567222 2026-05-06

Clinical Study of Novel Therapeutic Vaccine for Advanced Solid Tumors

Phase 1 Recruiting

Neoplasms

NCT03712943 2026-02-09

Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer

Phase 1 Completed

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT04362839 2026-01-28

Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer

Phase 1 Completed

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05155189 2026-01-21

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

Phase 1 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06095375 2026-01-09

REGOMA-2

Phase 1 Completed

Glioblastoma

NCT03042689 2026-01-08

Study of Regorafenib in Patients With Advanced Myeloid Malignancies

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06283134 2026-01-07

A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer

Phase 1 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05830084 2026-01-06

REGO-INTER-EWI

Phase 1 Active not recruiting

Sarcoma, Ewing

NCT06454409 2025-11-19

Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Suspended

MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03406871 2025-01-24

REGONIVO

Phase 1 Completed

50 enrolled 14 charts

Neoplasm Metastasis

NCT02085148 2024-04-22

A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy

Phase 1 Completed

CNSGastrointestinalGenitourinarySarcoma

Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Hepatoblastoma

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT06283303 2024-02-29

A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer

Phase 1 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT06200363 2024-01-11

A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer

Phase 1 Unknown

Gastrointestinal

Advanced Colorectal Cancer

NCT03215264 2023-11-09

To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer

Phase 1 Completed

20 enrolled 9 charts

Gastrointestinal

Colorectal Neoplasms

NCT03347292 2023-07-25

Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC

Phase 1 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02910843 2023-01-10

RECAP

Phase 1 Terminated

Gastrointestinal

Rectal Neoplasms

NCT05644392 2022-12-09

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours

Phase 1 Unknown

Gastrointestinal

Advanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic Therapy

NCT03475251 2022-02-18

A Study of CS1003 in Subjects With Advanced Solid Tumors

Phase 1 Completed

Advanced Cancer

NCT02439723 2021-06-23

Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients

Phase 1 Withdrawn

Metastatic Solid Malignancies

NCT02164240 2021-06-14

SURE

Phase 1 Completed

14 enrolled 8 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT02095054 2021-04-01

Regorafenib and Cetuximab in Patients With Advanced Malignancy

Phase 1 Completed

Neoplasm Metastasis

NCT04819516 2021-03-29

Study of the Safety and Effectiveness of HIFU Combined With REGOTORI for Metastatic Colorectal Cancer

Phase 1 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT03305913 2021-03-26

REMETY

Phase 1 Completed

Gastrointestinal

Pretreated Metastatic Colorectal Cancer

NCT03081494 2020-12-11

Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer

Phase 1 Completed

Gastrointestinal

Colorectal Neoplasms

NCT02466802 2020-02-20

Study of Regorafenib and Sildenafil for Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

Solid Tumor

NCT01287598 2019-07-10

BAY73-4506 Probe Substrate Study

Phase 1 Completed

Neoplasms

NCT02106845 2019-06-07

Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.

Phase 1 Completed

Neoplasms

NCT01973868 2019-04-09

Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination

Phase 1 Completed

Neoplasms

NCT02116894 2019-03-14

REGAL-1

Phase 1 Completed

Gastrointestinal

Colorectal Neoplasms

NCT02168777 2018-01-26

Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer

Phase 1 Terminated

20 enrolled 28 charts

Neoplasms

NCT00960258 2017-09-27

Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.

Phase 1 Completed

Neoplasms

NCT01853046 2017-02-20

Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

Phase 1 Completed

24 enrolled 30 charts

Neoplasms, Renal Insufficiency

NCT02199223 2016-09-22

Regorafenib + Panitumumab for Colorectal Cancers

Phase 1 Terminated

Gastrointestinal

KRAS and NRAS Wild-type Colorectal Cancer

NCT02398513 2016-08-01

Regorafenib Phase I Study in Mainland Chinese Patients

Phase 1 Completed

Neoplasms

NCT01117623 2015-11-18

Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies

Phase 1 Completed

86 enrolled 33 charts

Neoplasms

NCT02001909 2015-08-13

Effect of Neomycin on the Pharmacokinetics of Regorafenib

Phase 1 Completed

Neoplasms

NCT01322438 2014-12-19

Effect of Rifampin on the Pharmacokinetics of BAY73-4506

Phase 1 Completed

Neoplasms

NCT01339104 2014-10-01

Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity

Phase 1 Completed

Neoplasms

NCT01187615 2014-07-08

Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer

Phase 1 Terminated

Small Cell Lung Carcinoma

NCT00934882 2014-06-02

Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI

Phase 1 Completed

Gastrointestinal

Colorectal Neoplasms

NCT01096030 2013-11-19

Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors

Phase 1 Completed

Neoplasms